

Vaccine price commitments from manufacturers

Several manufacturers have made commitments to continue providing Gavi countries with access to the same price as Gavi pays, or to maintain the prices countries are currently paying for certain vaccines for set periods of time after they have transitioned out of Gavi’s financial support. These countries would fully self-finance these vaccine purchases. The links at the end of this document explain in more detail each of the manufacturer commitments.

The terms ‘transitioned’ and ‘fully self-financing’ in manufacturer’s commitment documents refer to countries that have transitioned out of Gavi’s financial support, as defined by the Gavi [Eligibility and Transition](#), and [Co-financing](#) policies in effect as of January 2016.

Please note that Gavi is providing the information on this page and those linked below for informational purposes only. This information is meant for the convenience and benefit of countries and should not give a false sense of assurance that Gavi is “guaranteeing” prices, and that prices are determined for every single product and country. Rather, these manufacturer commitments are intended to help with country budgeting, but ultimately the decision lies with the individual manufacturer to offer a country a price matching its policies within a tender.

Gavi recognises the need for visibility is very important for countries, most of all when they are doing rapid increases in budget during the accelerated transition phase. Countries should use the Gavi public price forecast available on the Gavi country portal as their best indication of price for specific presentations of different vaccines.

The mention of specific companies or of certain manufacturers’ products does not imply that Gavi endorses or recommends these products in preference of others of a similar nature that are not mentioned.

	Biological E	Glaxo-SmithKline (GSK)	Janssen Pharmaceuticals	Merck	Panacea Biotec	Pfizer
Pentavalent	✓		✓		✓	
Pneumococcal (PCV)		✓				✓
Rotavirus		✓		✓		
Human Papilloma Virus (HPV)		✓		✓		

RELATED DOWNLOADS (click on each link below for access to individual FAQs)

FAQ: Biological E pricing commitments for countries transitioning out of Gavi’s financial support

FAQ: GlaxoSmithKline pricing commitments for countries transitioning out of Gavi’s financial support

FAQ: Janssen Pharmaceuticals pricing commitments for countries transitioning out of Gavi’s financial support

FAQ: Merck pricing commitments for countries transitioning out of Gavi’s financial support

FAQ: Panacea Biotec pricing commitments for countries transitioning out of Gavi’s financial support

FAQ: Pfizer pricing commitments for countries transitioning out of Gavi’s financial support